---
category: listing
circular_id: 12433fb68cbdbfcf
date: '2025-08-12'
description: 1,08,62,500 new equity shares of Valiant Laboratories Ltd listed on BSE
  with effect from August 13, 2025.
draft: false
guid: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={F8A4A06A-034C-4C57-966D-6FEBE1804242}&noticeno=20250812-36&dt=08/12/2025&icount=36&totcount=50&flag=0
impact: low
impact_ranking: low
importance_ranking: low
justification: Routine listing of new securities from rights issue with no market
  disruption
pdf_url: https://www.bseindia.com/markets/MarketInfo/DownloadAttach.aspx?id=20250812-36&attachedId=
processing:
  attempts: 1
  content_hash: 8e54dd1826d77554
  processed_at: '2025-08-12T18:35:26.287167'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-08-12T13:07:08+00:00'
rss_url: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={F8A4A06A-034C-4C57-966D-6FEBE1804242}&noticeno=20250812-36&dt=08/12/2025&icount=36&totcount=50&flag=0
severity: low
source: bse
stocks:
- VALIANT
tags:
- equity
- listing
- new-securities
- rights-issue
title: Listing of New Securities of Valiant Laboratories Ltd.
---

## Summary

BSE has announced the listing of 1,08,62,500 new equity shares of Valiant Laboratories Ltd (Scrip Code: 543998) issued through a rights offering. The shares will commence trading on August 13, 2025.

## Key Points

- 1,08,62,500 equity shares of Rs. 10/- each issued at premium of Rs. 65/-
- Shares issued on rights basis to existing shareholders
- ISIN: INE0JWS01017
- Distribution Numbers: 43450001 to 54312500
- Date of Allotment: August 11, 2025
- New shares rank pari-passu with existing equity shares

## Regulatory Changes

No regulatory changes introduced.

## Compliance Requirements

Trading members are informed of the new securities availability for trading from the effective date.

## Important Dates

- **Allotment Date**: August 11, 2025
- **Trading Commencement**: August 13, 2025

## Impact Assessment

Routine corporate action with minimal market impact. The rights issue increases the company's equity base and provides existing shareholders with additional investment opportunity at a premium to face value.